-
Ewopharma and CStone enter into a Strategic Partnership for Sugemalimab in Central Eastern Europe and Switzerland
Ewopharma announces today that it has entered into a strategic commercial collaboration with CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovationdriven biopharmaceutical company focused on the research and development of anti-cancer therapies. Under the agreement, Ewopharma will gain the commercial rights for sugemalimab in Switzerland and 18 Central Eastern European countries (CEE). These include EU member countries Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, and Slovenia, as well as non- EU countries Albania, Bosnia & Herzegovina, Kosovo, North Macedonia, Moldova, Montenegro, Serbia. The partnership will maximize the value of sugemalimab (anti-PD-L1 monoclonal antibody) in Central Eastern Europe and Switzerland. CStone will receive up to $51.3 million in…
-
Neomed s.r.o. becomes part of Ewopharma Group
Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of Neomed s.r.o., a Czech Distribution company of pharmaceuticals, medical devices, and cosmetics. As part of a succession solution, the Ewopharma Group was able to acquire Neomed s.r.o. as of 1 June 2023. In the past, Ewopharma and Neomed enjoyed several specific, successful collaborations in the region. Over the past years, Ewopharma has successfully grown the business and continued to expand geographically. The acquisition opens new expertise for Ewopharma, this with Neomed’s existing staff and partnerships. Mr. Alain Staub, CEO of the Ewopharma Group, commented “This is an important…
